1 / 8

PRIMARY

THE DISEASE Raising Incidence : 6000 nc / yr , 1500 dead/ yr Younger patients !!. A PREVENTABLE DISEASE !!! . IMPROVED Prevention and Early Diagnosis reduced Mortality Rate with Screening Programs ( J. Invest . Dermatol 132:1311.2012). Prognosis. METASTATIC .

torie
Télécharger la présentation

PRIMARY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. THE DISEASE RaisingIncidence: 6000 nc/yr , 1500 dead/yrYoungerpatients !! A PREVENTABLE DISEASE !!! IMPROVED Prevention and EarlyDiagnosis reducedMortality Rate with Screening Programs ( J. Invest. Dermatol 132:1311.2012) Prognosis METASTATIC PRIMARY High Cure Rates UntilRecently……

  2. The Biology VGP RGP MolecularCharacterizationofTumorProgression B E F D MotilityInvasion Growth C Loss of keratinocytes control Angiogenesis Fibroblasts ECM ECM

  3. TranslationalRelevance Table 3. Antigenic Phenotype of ABCG+ IGR37 melanoma xenograft DifferentiationAgsProgressionAgsCancertestisAgs HMW-MAA positive CD9 positive NY-ESO-1 negative HBM-45 positive c-met positive MAGE-A positive Melan-A positive HER-3 positive ET-Br positive Tenascinpositive ET-1 negative PlosOneDec,2010 Imaging Gene Array S L N “Stem” Cells Smallmolecules target therapy Immuno-therapy Agonistic and AntagonistRecepotrs

  4. Table 3. Antigenic Phenotype of ABCG+ IGR37 melanoma xenograft Differentiation Antigens Progression antigens Cancertestis antigens HMW-MAA positive CD9 positive NY-ESO-1 negative HBM-45 positive c-met positive MAGE-A positive Melan-A positive HER-3 positive ET-Br positive Tenascinpositive ET-1 negative PlosOneDec,2010

  5. THE DISEASE Incidence: 6000 nc/yr , 1500 dead/yr Prognosis METASTATIC PRIMARY Resistant…….. toavailabletherapies IMPROVED Prevention and EarlyDiagnosis High Cure Rates A PREVENTABLE DISEASE !!!

  6. THE DISEASE Incidence: 6000 nc/yr , 1500 dead/yr IMPROVED Prevention and EarlyDiagnosis A PREVENTABLE DISEASE !!!

More Related